Sign in Subscribe
Pharmaceutical industry

Genprex Inc. Advances Lead Product REQORSA for Non-Small Cell Lung Cancer, Expands into Diabetes Gene Therapy

Strategic Insights

— 2 min read

Genprex Inc., a clinical-stage gene therapy company, is focusing on developing life-changing therapies for patients with cancer and diabetes. Its lead product candidate, REQORSA immunogene therapy, is being developed for non-small cell lung cancer (NSCLC) and has received Fast Track Designation from the US FDA. Genprex has also formed a Clinical Advisory Board to support its oncology and diabetes development programs. Additionally, the company has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could potentially cure Type 1 and Type 2 diabetes.

Key Takeaways:

  • Genprex Inc. is a clinical-stage gene therapy company developing life-changing therapies for patients with cancer and diabetes.
  • REQORSA immunogene therapy, the company's lead product candidate, is being developed for non-small cell lung cancer (NSCLC) and has received Fast Track Designation from the US FDA.
  • REQORSA uses a unique ONCOPREX nanoparticle delivery system, which provides cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles.
  • The company has formed a Clinical Advisory Board to support its oncology and diabetes development programs.
  • Genprex has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could potentially cure Type 1 and Type 2 diabetes.
  • The company has a strong balance sheet with $40 million in capital infusions in 2020 and plans to initiate both Acclaim trials in the first half of 2021.
  • Genprex is listed on the NASDAQ and New York Stock Exchange, and inclusion in the Russell 3000 Index has increased its visibility among institutional investors, money managers, and index funds.
  • The company's CEO, Rodney Varner, states that various significant milestones in 2020 have set the stage for a transformational 2021.

Statistics:

  • Genprex has $40 million in capital infusions in 2020.
  • The company plans to initiate both Acclaim trials in the first half of 2021.
  • Lung cancer is the leading cause of cancer deaths worldwide.
  • NSCLC patients with EFGR mutations have a better prognosis with the combination of REQORSA and Tagrisso.
  • Tagrisso has had worldwide sales in the billions of dollars.
  • Acclaim-1 is a Phase 1/2 combination clinical trial using REQORSA combined with AstraZeneca's Tagrisso in patients with late-stage NSCLC whose disease progressed after treatment with Tagrisso.
  • Acclaim-2 is a Phase 1/2 combination clinical trial using REQORSA combined with Merck & Co Inc's Keytruda in NSCLC patients who are low expressors of PD-L1.

Sources:

  • Genprex Inc. (NASDAQ:GNPX)
  • University of Pittsburgh
  • AstraZeneca PLC (NYSE:AZN)
  • Merck & Co Inc (NYSE:MRK)
  • American Association for Cancer Research
  • US FDA
  • Rodney Varner, CEO of Genprex Inc.

Read more